Update of the M. D. Anderson Cancer Center Experience with Hyper-CVAD and Rituximab for the Treatment of Mantle Cell and Burkitt-Type Lymphomas
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference18 articles.
1. The World Health Organization for neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Arlie House, Virginia, November 1997;Harris;Histopathology,2000
2. Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
3. Molecular diagnosis of Burkitt's lymphoma;Dave;N Engl J Med,2006
4. Adults and children with small noncleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen;Magrath;J Clin Oncol,1996
5. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia;Thomas;J Clin Oncol,1999
Cited by 49 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Burkitt's Lymphoma;Comprehensive Hematology and Stem Cell Research;2024
2. Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL;Experimental Hematology;2021-09
3. Comparison in safety of chemotherapy protocols for blood cancers: toxicity of H-CVAD versus GELA/BURKIMAB/PETHEMA LAL;ecancermedicalscience;2021-03-22
4. Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review;Critical Reviews in Oncology/Hematology;2021-02
5. Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies;British Journal of Haematology;2020-11-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3